[{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beckley Psytech \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Through the acquisition, combined portfolio will advance well-protected deuterated DMT program, including SPL026 (N,N-dimethyltryptamine) for the potential treatment of Major Depressive Disorder (MDD).

                          Product Name : SPL026

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          October 23, 2023

                          Lead Product(s) : Dimethyltryptamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Cybin

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : SPL026, is a proprietary synthetic formulation of N,N-dimethyltryptamine [DMT] fumarate, a psychedelic tryptamine being developed as a supportive therapy for patients with mental health conditions or major depressive disorder.

                          Product Name : SPL026

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          September 27, 2023

                          Lead Product(s) : Dimethyltryptamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : SPL026, is a proprietary synthetic formulation of N,N-dimethyltryptamine [DMT] fumarate, a psychedelic tryptamine being developed as a supportive therapy for patients with mental health conditions or major depressive disorder.

                          Product Name : SPL026

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          September 26, 2023

                          Lead Product(s) : Dimethyltryptamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Together, the combined operating teams of Cybin and Small Pharma create a sector-leading organization with deep expertise in N,N-dimethyltryptamine (DMT, SPL026) and deuterated psychedelic tryptamine-based therapeutics for mental health disorders.

                          Product Name : SPL026

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          August 28, 2023

                          Lead Product(s) : Dimethyltryptamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Cybin

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : SPL026, is a proprietary synthetic formulation of DMT (N,N-dimethyltryptamine). It is a psychedelic tryptamine being developed as a therapy for patients with major depressive disorder (MDD).

                          Product Name : SPL026

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          July 03, 2023

                          Lead Product(s) : Dimethyltryptamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : SPL026, is a proprietary synthetic formulation of N,N-dimethyltryptamine [DMT] fumarate, a psychedelic tryptamine being developed as a supportive therapy for patients with mental health conditions or major depressive disorder.

                          Product Name : SPL026

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          April 04, 2023

                          Lead Product(s) : Dimethyltryptamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : SPL026, is a proprietary synthetic formulation of DMT (N,N-dimethyltryptamine). It is a psychedelic tryptamine being developed as a therapy for patients with major depressive disorder (MDD).

                          Product Name : SPL026

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          January 25, 2023

                          Lead Product(s) : Dimethyltryptamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Small Pharma’s lead candidate, SPL026, is a proprietary synthetic formulation of DMT. The Company is advancing a clinical program of intravenous SPL026 with supportive therapy for the treatment of major depressive disorder.

                          Product Name : SPL026

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          December 22, 2022

                          Lead Product(s) : Dimethyltryptamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The trial will assess a single dose of SPL026 (N,N-dimethyltryptamine) in patients currently on a treatment course of SSRIs that have been ineffective in fully relieving their depression, compared to patients who are not currently using any treatment to ...

                          Product Name : SPL026

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          December 15, 2022

                          Lead Product(s) : Dimethyltryptamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : SPL026, is a proprietary synthetic formulation of DMT being developed as a therapy for patients with major depressive disorder (MDD),to be administered by IV injection.

                          Product Name : SPL026

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          October 19, 2022

                          Lead Product(s) : Dimethyltryptamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank